NASDAQ NMS - GLOBAL MARKET · ALKS
-0.12% · -$0.0600 · Vol 1.7M
After hours · updated 16:00:56 ET
Alkermes Plc

Alkermes Plc

Biotechnology
$49.61
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
ALKS
Alkermes Plc
Tue Aug 4 · last completed session · Markets closed · resumes Thu 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

74/ 100
Veridion Score
BUY BIAS · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Tue Aug 4 · last completed session · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ALKS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ALKS catalysts
About Alkermes Plc
PHARMACEUTICAL PREPARATIONS
Listed since
1991
Employees
2K
Country
IE

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$50.20
Day high
$50.85
Day low
$49.23
Previous close
$49.67
52W high
$55.22
-10.16% from high
52W low
$26.52
80% of range
Market cap
$8.3B
P/E
81.33×
EPS
$0.6100
Beta
0.77
Shares out
167.8M
Volume
1.7M
0.78× rel vol
Avg volume
2.2M
VWAP
$49.85
Price history computed in-house
1W
+2.63%
1M
-10.03%
3M
+40.14%
1Y
+86.50%
YTD
+77.31%
SMA 50 $48.23 · above
SMA 200 $35.67 · above
52W position 80%

ALKS overview

Veridion Score
74
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ALKS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ALKS Form 4 filings
Public disclosures

Congress activity in ALKS

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ALKS in the cached public ledger.

Federal contracts

ALKS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ALKS in this window.
Lobbying spend

ALKS lobbying filings, year to date.

Registered lobbying filings matched to Alkermes Plc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ALKS in this window.
Loading news for ALKS
Analyst ratings
Sovereign unlock shows live analyst consensus for ALKS.
Options
Sovereign unlock shows live options positioning for ALKS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.